Brigatinib was subsequently approved for first‐line treatment of ALK+ NSCLC based on results of the phase III ALK in Lung Cancer Trial of brigAtinib in First Line (ALTA‐1L; NCT02737501) comparing the efficacy and safety of brigatinib versus crizotinib in patients with advanced ALK inhibitor‐naive ALK+ NSCLC.7, 8. Here, ALK is linked to non-small cell lung carcinoma.